RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened

• On March 1, 2026 Rhythm Pharmaceuticals, Inc. announced additional data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity. The company furnished the March 1 press release as Exhibit 99.1 to a Form 8‑K filed March 2, 2026 (Item 7.01/8.01).
• The filing notes the statistical approach used to estimate treatment-group differences: an ANCOVA model allowing unequal residual variances and Rubin’s Rule to combine least‑square mean estimates, confidence intervals and p‑values.

Key Details

• Date of disclosure: March 1, 2026 (press release); Form 8‑K filed March 2, 2026.
• Program: setmelanotide in the global Phase 3 TRANSCEND trial for acquired hypothalamic obesity.
• Disclosure type: Regulation FD / Item 7.01 (press release furnished as Exhibit 99.1).
• Statistical methods referenced: ANCOVA with unequal variance and Rubin’s Rule for pooled estimates.

Why It Matters

• This is a material clinical update for Rhythm’s lead obesity program — additional Phase 3 data can influence investor perception of the drug’s efficacy/safety and the company’s clinical progress.
• The Regulation FD filing makes the information public and available to all investors; watch for follow‑up filings or presentations that provide specific efficacy, safety, enrollment or regulatory‑timing details that could affect the stock or development timeline.